VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held biotechnology company focused on the development of next generation antibody-based therapeutics, today announced the close of a financing totaling $3.2 million. The financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, L.P. (“CTI”) which led the Company’s previous financing in 2009. Further financial terms are not disclosed. Zymeworks will use the proceeds to advance its antibody-engineering platform and research programs focused on the development of Zymeworks’ best-in-class protein therapeutics pipeline.
